James Zackheim, PhD, is Vice President – Patient Solutions Team for Neupro® (Rotigotine Transdermal System). He is responsible for providing leadership and strategic direction for all aspects of the product and for ensuring delivery of the best possible solutions to patients living with Parkinson’s disease and Restless Legs Syndrome.
Dr. Zackheim joined UCB in 2004 and, prior to his current role, he served as the Senior Medical Director for UCB’s Central Nervous System (CNS) Business Unit in the U.S. Dr. Zackheim oversaw medical leadership for the launch of Vimpat® (lacosamide) in 2009 and Neupro® in 2012, contributing to excellent initial launch results through customer insight, relevant clinical data, and forming key partnerships.
Known for his creative, innovative thinking, Dr. Zackheim also spearheaded the development, from concept to production, of cutting-edge, patentable medical education e-tools to improve communication between patients and physicians.
Dr. Zackheim graduated from the University of Leeds, England, in 1995, with a Bachelor of Science in Cognitive Science. He received a Master of Science in Neurological Science from the University College of London, England, in 1996, and his PhD in Integrative Neuroscience from Rutgers University, New Jersey, in 2003